BeOne Medicines AG (ONC)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-05) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-06) · 99.1 | 8-K (2026-04-14) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-26) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | 8-K (2025-08-29) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-06) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-07) · 99.1 | 8-K (2025-04-28) · 99.1 | ||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | 8-K (2025-02-27) · 99.1 | ||
| 10-K/A | FY-2023 | |||
| 10-Q | Q3-2024 | 8-K (2024-11-12) · 99.1 | 8-K (2024-08-29) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-07) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | 8-K (2024-04-26) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-26) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-09) · 99.1 | 8-K (2023-08-29) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Comprehensive Income | — |
|
| Consolidated Balance Sheets | ||
| Consolidated Statements of Comprehensive Income (loss) | ||
| Consolidated Statements of Comprehensive Loss | — |
|
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Shareholders Equity | ||
| Notes | ||
| (loss) Earnings Per Share | — |
|
| Accumulated Other Comprehensive (loss) Income | — |
|
| Accumulated Other Comprehensive Loss | — |
|
| Collaborative and Licensing Arrangements | ||
| Collaborative, Licensing and Other Arrangements | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Debt | ||
| Description of Business | — |
|
| Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies | — |
|
| Earnings (loss) Per Share | — |
|
| Earnings (loss) Per Share/ads | ||
| Earnings Per Share/ads | — |
|
| Employee Benefit Plans | — |
|
| Fair Value Measurements | — |
|
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Assets | ||
| Inventories, Net | ||
| Investments | — |
|
| Leases | — |
|
| Loss Per Share | ||
| Organization | — |
|
| Pay Vs Performance Disclosure | ||
| Product Revenue | ||
| Property, Plant and Equipment, Net | ||
| Restricted Cash | — |
|
| Restricted Cash and Investments | — |
|
| Restricted Net Assets | ||
| Sale of Future Imdelltra Royalties | ||
| Sale of Future Imdelltraâ® Royalties | — |
|
| Schedule I | — |
|
| Segment and Geographic Information | ||
| Share-based Compensation | — |
|
| Share-based Compensation Expense | — |
|
| Shareholders Equity | ||
| Summary of Significant Accounting Policies | — |
|
| Supplemental Balance Sheet Information | ||